Brandeis Seymore, RPh, MPBA Candidate

In an era of high-priced drugs, health care stakeholders continue to explore alternative pricing models that focus on the concept of value-based drug purchasing models.

The cause of the majority of rare diseases is associated with 80% of the cases being genetically linked due to inheritance of mutated genes.

The growth of the pipeline has led to increases in insurance carriers’ specialty plan spend.

Specialty pharmacies can provide seamless support across specialty mail and retail channels.

Several viable models continue to emerge for addressing the unique challenges of payment and financing for innovative, durable, curative gene and cell therapies.